Global Biotherapeutics Cell Line Development 麻豆原创 Research Report 2024

Publication ID:

PB503241647

Publication Date:

March 14, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Biotherapeutics Cell Line Development market was valued at US$ 390.7 million in 2023 and is anticipated to reach US$ 591.8 million by 2030, witnessing a CAGR of 6.2% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Biotherapeutics Cell Line Development, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Biotherapeutics Cell Line Development.
Report Scope
The Biotherapeutics Cell Line Development market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Biotherapeutics Cell Line Development market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Biotherapeutics Cell Line Development companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
Becton Dickinson & Company
Beckman Coulter
Boehringer Ingelheim Group
Catalent Inc.
CMC Biologics A/S
Lonza Group Ltd.
EMD Millipore
Partec (Sysmex Corporation)
ProBioGen AG
Selexis SA
Sigma-Aldrich Co. LLC.
Sony Biotechnology Inc.
Thermo Fisher Scientific Inc.
Segment by Type
Transfection & Selection
Single Cell Cloning
Segment by Application
In-house
Outsource
Hybrid
Do-It-Yourself (DIY)
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Biotherapeutics Cell Line Development companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Biotherapeutics Cell Line Development 麻豆原创 Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Transfection & Selection
1.2.3 Single Cell Cloning
1.3 麻豆原创 by Application
1.3.1 Global Biotherapeutics Cell Line Development 麻豆原创 Growth by Application: 2019 VS 2023 VS 2030
1.3.2 In-house
1.3.3 Outsource
1.3.4 Hybrid
1.3.5 Do-It-Yourself (DIY)
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Biotherapeutics Cell Line Development 麻豆原创 Perspective (2019-2030)
2.2 Biotherapeutics Cell Line Development Growth Trends by Region
2.2.1 Global Biotherapeutics Cell Line Development 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
2.2.2 Biotherapeutics Cell Line Development Historic 麻豆原创 Size by Region (2019-2024)
2.2.3 Biotherapeutics Cell Line Development Forecasted 麻豆原创 Size by Region (2025-2030)
2.3 Biotherapeutics Cell Line Development 麻豆原创 Dynamics
2.3.1 Biotherapeutics Cell Line Development Industry Trends
2.3.2 Biotherapeutics Cell Line Development 麻豆原创 Drivers
2.3.3 Biotherapeutics Cell Line Development 麻豆原创 Challenges
2.3.4 Biotherapeutics Cell Line Development 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Biotherapeutics Cell Line Development Players by Revenue
3.1.1 Global Top Biotherapeutics Cell Line Development Players by Revenue (2019-2024)
3.1.2 Global Biotherapeutics Cell Line Development Revenue 麻豆原创 Share by Players (2019-2024)
3.2 Global Biotherapeutics Cell Line Development 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Biotherapeutics Cell Line Development Revenue
3.4 Global Biotherapeutics Cell Line Development 麻豆原创 Concentration Ratio
3.4.1 Global Biotherapeutics Cell Line Development 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Biotherapeutics Cell Line Development Revenue in 2023
3.5 Biotherapeutics Cell Line Development Key Players Head office and Area Served
3.6 Key Players Biotherapeutics Cell Line Development Product Solution and Service
3.7 Date of Enter into Biotherapeutics Cell Line Development 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Biotherapeutics Cell Line Development Breakdown Data by Type
4.1 Global Biotherapeutics Cell Line Development Historic 麻豆原创 Size by Type (2019-2024)
4.2 Global Biotherapeutics Cell Line Development Forecasted 麻豆原创 Size by Type (2025-2030)
5 Biotherapeutics Cell Line Development Breakdown Data by Application
5.1 Global Biotherapeutics Cell Line Development Historic 麻豆原创 Size by Application (2019-2024)
5.2 Global Biotherapeutics Cell Line Development Forecasted 麻豆原创 Size by Application (2025-2030)
6 North America
6.1 North America Biotherapeutics Cell Line Development 麻豆原创 Size (2019-2030)
6.2 North America Biotherapeutics Cell Line Development 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Biotherapeutics Cell Line Development 麻豆原创 Size by Country (2019-2024)
6.4 North America Biotherapeutics Cell Line Development 麻豆原创 Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Biotherapeutics Cell Line Development 麻豆原创 Size (2019-2030)
7.2 Europe Biotherapeutics Cell Line Development 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Biotherapeutics Cell Line Development 麻豆原创 Size by Country (2019-2024)
7.4 Europe Biotherapeutics Cell Line Development 麻豆原创 Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Biotherapeutics Cell Line Development 麻豆原创 Size (2019-2030)
8.2 Asia-Pacific Biotherapeutics Cell Line Development 麻豆原创 Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Biotherapeutics Cell Line Development 麻豆原创 Size by Region (2019-2024)
8.4 Asia-Pacific Biotherapeutics Cell Line Development 麻豆原创 Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Biotherapeutics Cell Line Development 麻豆原创 Size (2019-2030)
9.2 Latin America Biotherapeutics Cell Line Development 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Biotherapeutics Cell Line Development 麻豆原创 Size by Country (2019-2024)
9.4 Latin America Biotherapeutics Cell Line Development 麻豆原创 Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Biotherapeutics Cell Line Development 麻豆原创 Size (2019-2030)
10.2 Middle East & Africa Biotherapeutics Cell Line Development 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Biotherapeutics Cell Line Development 麻豆原创 Size by Country (2019-2024)
10.4 Middle East & Africa Biotherapeutics Cell Line Development 麻豆原创 Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Becton Dickinson & Company
11.1.1 Becton Dickinson & Company Company Detail
11.1.2 Becton Dickinson & Company Business Overview
11.1.3 Becton Dickinson & Company Biotherapeutics Cell Line Development Introduction
11.1.4 Becton Dickinson & Company Revenue in Biotherapeutics Cell Line Development Business (2019-2024)
11.1.5 Becton Dickinson & Company Recent Development
11.2 Beckman Coulter
11.2.1 Beckman Coulter Company Detail
11.2.2 Beckman Coulter Business Overview
11.2.3 Beckman Coulter Biotherapeutics Cell Line Development Introduction
11.2.4 Beckman Coulter Revenue in Biotherapeutics Cell Line Development Business (2019-2024)
11.2.5 Beckman Coulter Recent Development
11.3 Boehringer Ingelheim Group
11.3.1 Boehringer Ingelheim Group Company Detail
11.3.2 Boehringer Ingelheim Group Business Overview
11.3.3 Boehringer Ingelheim Group Biotherapeutics Cell Line Development Introduction
11.3.4 Boehringer Ingelheim Group Revenue in Biotherapeutics Cell Line Development Business (2019-2024)
11.3.5 Boehringer Ingelheim Group Recent Development
11.4 Catalent Inc.
11.4.1 Catalent Inc. Company Detail
11.4.2 Catalent Inc. Business Overview
11.4.3 Catalent Inc. Biotherapeutics Cell Line Development Introduction
11.4.4 Catalent Inc. Revenue in Biotherapeutics Cell Line Development Business (2019-2024)
11.4.5 Catalent Inc. Recent Development
11.5 CMC Biologics A/S
11.5.1 CMC Biologics A/S Company Detail
11.5.2 CMC Biologics A/S Business Overview
11.5.3 CMC Biologics A/S Biotherapeutics Cell Line Development Introduction
11.5.4 CMC Biologics A/S Revenue in Biotherapeutics Cell Line Development Business (2019-2024)
11.5.5 CMC Biologics A/S Recent Development
11.6 Lonza Group Ltd.
11.6.1 Lonza Group Ltd. Company Detail
11.6.2 Lonza Group Ltd. Business Overview
11.6.3 Lonza Group Ltd. Biotherapeutics Cell Line Development Introduction
11.6.4 Lonza Group Ltd. Revenue in Biotherapeutics Cell Line Development Business (2019-2024)
11.6.5 Lonza Group Ltd. Recent Development
11.7 EMD Millipore
11.7.1 EMD Millipore Company Detail
11.7.2 EMD Millipore Business Overview
11.7.3 EMD Millipore Biotherapeutics Cell Line Development Introduction
11.7.4 EMD Millipore Revenue in Biotherapeutics Cell Line Development Business (2019-2024)
11.7.5 EMD Millipore Recent Development
11.8 Partec (Sysmex Corporation)
11.8.1 Partec (Sysmex Corporation) Company Detail
11.8.2 Partec (Sysmex Corporation) Business Overview
11.8.3 Partec (Sysmex Corporation) Biotherapeutics Cell Line Development Introduction
11.8.4 Partec (Sysmex Corporation) Revenue in Biotherapeutics Cell Line Development Business (2019-2024)
11.8.5 Partec (Sysmex Corporation) Recent Development
11.9 ProBioGen AG
11.9.1 ProBioGen AG Company Detail
11.9.2 ProBioGen AG Business Overview
11.9.3 ProBioGen AG Biotherapeutics Cell Line Development Introduction
11.9.4 ProBioGen AG Revenue in Biotherapeutics Cell Line Development Business (2019-2024)
11.9.5 ProBioGen AG Recent Development
11.10 Selexis SA
11.10.1 Selexis SA Company Detail
11.10.2 Selexis SA Business Overview
11.10.3 Selexis SA Biotherapeutics Cell Line Development Introduction
11.10.4 Selexis SA Revenue in Biotherapeutics Cell Line Development Business (2019-2024)
11.10.5 Selexis SA Recent Development
11.11 Sigma-Aldrich Co. LLC.
11.11.1 Sigma-Aldrich Co. LLC. Company Detail
11.11.2 Sigma-Aldrich Co. LLC. Business Overview
11.11.3 Sigma-Aldrich Co. LLC. Biotherapeutics Cell Line Development Introduction
11.11.4 Sigma-Aldrich Co. LLC. Revenue in Biotherapeutics Cell Line Development Business (2019-2024)
11.11.5 Sigma-Aldrich Co. LLC. Recent Development
11.12 Sony Biotechnology Inc.
11.12.1 Sony Biotechnology Inc. Company Detail
11.12.2 Sony Biotechnology Inc. Business Overview
11.12.3 Sony Biotechnology Inc. Biotherapeutics Cell Line Development Introduction
11.12.4 Sony Biotechnology Inc. Revenue in Biotherapeutics Cell Line Development Business (2019-2024)
11.12.5 Sony Biotechnology Inc. Recent Development
11.13 Thermo Fisher Scientific Inc.
11.13.1 Thermo Fisher Scientific Inc. Company Detail
11.13.2 Thermo Fisher Scientific Inc. Business Overview
11.13.3 Thermo Fisher Scientific Inc. Biotherapeutics Cell Line Development Introduction
11.13.4 Thermo Fisher Scientific Inc. Revenue in Biotherapeutics Cell Line Development Business (2019-2024)
11.13.5 Thermo Fisher Scientific Inc. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

Becton Dickinson & Company
Beckman Coulter
Boehringer Ingelheim Group
Catalent Inc.
CMC Biologics A/S
Lonza Group Ltd.
EMD Millipore
Partec (Sysmex Corporation)
ProBioGen AG
Selexis SA
Sigma-Aldrich Co. LLC.
Sony Biotechnology Inc.
Thermo Fisher Scientific Inc.

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.